Bullish option flow detected in Biogen (BIIB) with 2,540 calls trading, 1.1x expected, and implied vol increasing over 2 points to 35.32%.

Shares of Biogen Inc. BIIB shed 1.16% to $141.43 Wednesday, on what proved to be an all-around great trading session for the ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

The stock's fall snapped a seven-day winning streak.

Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...

Deep-pocketed investors have adopted a bullish approach towards Biogen BIIB, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

MLB, Topps and Nike have partnered to recognize baseball's elite performers from last season with custom gold-embellished MLB logos on their jerseys that will then be used to create trading cards.

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...